Synergistic effect of the human GLP-1 analogue liraglutide and a dual PPARα/γ agonist on glycaemic control in Zucker diabetic fatty rats

Diabetes, Obesity and Metabolism

Volumn 11, Issue 8, 2009, Pages 795-803

  Brand, C L ^a   Galsgaard, E D ^a   Tornehave, D ^a   Romer J ^a   Gotfredsen, G F ^a   Wassermann, K ^a   Knudsen, L B ^a   Volund A ^a   Sturis, Jeppe ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Diabetes; Liraglutide; Zucker diabetic fatty (ZDF) rat

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; RAGAGLITAZAR; TRANSCRIPTION FACTOR PDX 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG POTENTIATION; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; MONOTHERAPY; NONHUMAN; PANCREAS ISLET BETA CELL; RAT; ZUCKER DIABETIC FATTY RAT;

ANIMALS; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HOMEODOMAIN PROTEINS; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-SECRETING CELLS; OXAZINES; PHENYLPROPIONATES; RATS; RATS, ZUCKER; TRANS-ACTIVATORS;

EID: 67650001888     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01049.x     Document Type: Article

References (22)

1. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-368.
2. Polonsky KS, Sturis J, Bell GI. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996; 334: 777-783.
3. Sturis J, Gotfredsen CF, Romer J et al. GLP-1 derivative liraglutide in rats with beta-cell deficiencies: Influence of metabolic state on beta-cell mass dynamics. Br J Pharmacol 2003; 140: 123-132.
4. Rolin B, Larsen MO, Gotfredsen CF et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002; 283: E745-E752.
5. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
6. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 2002; 359: 824-830.
7. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342.
8. Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377.
9. Saad MF, Greco S, Osei K et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: A 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 2004; 27: 1324-1329.
10. Brand CL, Sturis J, Gotfredsen CF et al. Dual PPAR alpha/gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab 2003; 284: E841-E854.
11. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998; 273: 3547-3550.
12. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A 1999; 96: 11513-11518.
13. Kawasaki F, Matsuda M, Kanda Y, Inoue H, Kaku K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/ db mice. Am J Physiol Endocrinol Metab 2005; 288: E510-E518.
14. Johansen T, Deckert M, Mandrup-Poulsen T, Malmöf K. The role of growth hormone and glucocorticoid in glucose handling in vivo. J Endocrinol 1999; 162: 87-93.
15. Gundersen HJG. The smooth fractionator. J Microsc 2002; 207: 191-210.
16. Wang Q, Dryden S, Frankish HM et al. Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol 1997; 122: 1405-1410.
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
18. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A 1994; 91: 10878-10882.
19. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. J Endocrinol 2000; 141: 4600-4605.
20. Harmon JS, Gleason CE, Tanaka Y, Oseid EA, Hunter-Berger KK, Robertson RP. In vivo prevention of hyperglycemia also prevents glucotoxic effects on PDX-1 and insulin gene expression. Diabetes 1999; 48: 1995-2000.
21. Li Y, Cao X, Li LX, Brubaker PL, Edlund H, Drucker DJ. beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 2005; 54: 482-491.
22. Larsen PJ, Wullf EM, Gotfredsen CF et al. Combination of the insulin sensitizer, pioglitazone, and the long-acting GLP-1 human analog, liraglutide, exerts potent synergistic glucose-lowering efficacy in severely diabetic ZDF rats. Diabetes Obes Metab 2008; 10: 301-311.